1. Scrip

In Brief: Mosaic Gains Two Clinical-Stage Oncology Assets From Astex

With This In-Licensing, Mosaic Evolves Into A Clinical-Stage Oncology Player

 
• By Sushmita Panda

Mosaic Therapeutics has in-licensed two clinical-stage oncology assets from Astex Pharmaceuticals to develop proprietary combination therapies for hard-to-treat cancers. The deal includes up to a 22% equity stake for Astex, future revenue sharing, and a planned clinical study in 2026.

Cancer Cells
The two small molecule assets from Astex are ASTX029 and ASTX295. (Shutterstock)

Mosaic Therapeutics is in-licensing of two clinical-stage oncology programs from Astex Pharmaceuticals in a deal that will significantly accelerate Mosaic’s development path, with its first clinical combination study expected to begin in 2026.

As part of the agreement, Astex, which is wholly owned by Japan’s Otsuka Pharmaceutical, has acquired a 19% equity stake in Mosaic upfront and will acquire a further 3% dependent...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Therapy Areas

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.